M. Verho

871 total citations
54 papers, 621 citations indexed

About

M. Verho is a scholar working on Cardiology and Cardiovascular Medicine, Pharmacology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, M. Verho has authored 54 papers receiving a total of 621 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 18 papers in Pharmacology and 14 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in M. Verho's work include Blood Pressure and Hypertension Studies (16 papers), Antibiotics Pharmacokinetics and Efficacy (15 papers) and Hormonal Regulation and Hypertension (10 papers). M. Verho is often cited by papers focused on Blood Pressure and Hypertension Studies (16 papers), Antibiotics Pharmacokinetics and Efficacy (15 papers) and Hormonal Regulation and Hypertension (10 papers). M. Verho collaborates with scholars based in Germany, France and Austria. M. Verho's co-authors include B Rangoonwala, F Cantarovich, Horst Lorenz, Vincent Esnault, V. Malerczyk, M. Badian, A. Korn, Péter Hajdú, Naresh Ranjith and N. Bender and has published in prestigious journals such as American Journal of Kidney Diseases, European Journal of Clinical Pharmacology and Journal of Cardiovascular Pharmacology.

In The Last Decade

M. Verho

53 papers receiving 563 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
M. Verho	179	177	170	85	83	54	621
Charles E. Halstenson	374 2.1×	250 1.4×	163 1.0×	156 1.8×	91 1.1×	53	1.3k
Andrew D. Blair	96 0.5×	270 1.5×	59 0.3×	76 0.9×	163 2.0×	31	901
Parviz Khajehdehi	295 1.6×	90 0.5×	60 0.4×	89 1.0×	67 0.8×	31	885
J. P. Kampmann	192 1.1×	192 1.1×	118 0.7×	107 1.3×	134 1.6×	27	1.1k
Paul A. Abraham	179 1.0×	120 0.7×	204 1.2×	57 0.7×	39 0.5×	34	854
L Dettli	99 0.6×	277 1.6×	70 0.4×	61 0.7×	85 1.0×	51	874
Maryam Pakfetrat	339 1.9×	109 0.6×	74 0.4×	75 0.9×	69 0.8×	67	1.1k
Maria de Fátima Fernandes Vattimo	170 0.9×	80 0.5×	42 0.2×	65 0.8×	79 1.0×	66	619
Xiao‐cong Zuo	220 1.2×	87 0.5×	64 0.4×	82 1.0×	126 1.5×	59	929
Juliana F. Roos	226 1.3×	151 0.9×	41 0.2×	77 0.9×	91 1.1×	12	617

Countries citing papers authored by M. Verho

Since Specialization

Citations

This map shows the geographic impact of M. Verho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Verho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Verho more than expected).

Fields of papers citing papers by M. Verho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Verho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Verho. The network helps show where M. Verho may publish in the future.

Co-authorship network of co-authors of M. Verho

This figure shows the co-authorship network connecting the top 25 collaborators of M. Verho. A scholar is included among the top collaborators of M. Verho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Verho. M. Verho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cantarovich, F, B Rangoonwala, Horst Lorenz, M. Verho, & Vincent Esnault. (2004). High-dose furosemide for established ARF: A prospective, randomized, double-blind, placebo-controlled, multicenter trial. American Journal of Kidney Diseases. 44(3). 402–409. 98 indexed citations

Ranjith, Naresh, et al.. (2002). Acute Myocardial Infarction in a Young South African Indian-based Population: Patient Characteristics on Admission and Gender-specific Risk Factor Prevalence. Current Medical Research and Opinion. 18(4). 242–248. 23 indexed citations

Soergel, Marianne, et al.. (2000). Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatric Nephrology. 15(1-2). 113–118. 31 indexed citations

Lorenz, Horst, et al.. (1998). Effects of Felodipine ER, a Dihydropyridine Calcium Antagonist, on Blood Pressure and Serum Lipids. Current Medical Research and Opinion. 14(2). 97–103. 3 indexed citations

Verho, M., et al.. (1996). Pharmacokinetics of Levofloxacin in Comparison to the Racemic Mixture of Ofloxacin in Man. Drug metabolism and drug interactions. 13(1). 57–68. 10 indexed citations

Cantarovich, F & M. Verho. (1996). A Simple Prognostic Index for Patients with Acute Renal Failure Requiring Dialysis. Renal Failure. 18(4). 585–592. 13 indexed citations

Verho, M., et al.. (1996). EFFICACY OF RAMIPRIL VERSUS ENALAPRIL IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION. International Journal of Clinical Practice. 50(6). 302–310. 6 indexed citations

Verho, M., Christian Lück, W. J. Stelter, B Rangoonwala, & N. Bender. (1995). Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Current Medical Research and Opinion. 13(5). 264–273. 23 indexed citations

Heintz, Bernhard, M. Verho, D. Brockmeier, et al.. (1993). Multiple-Dose Pharmacokinetics of Ramipril in Patients with Chronic Congestive Heart Failure. Journal of Cardiovascular Pharmacology. 22. S36–S36. 9 indexed citations

10.

Verho, M., et al.. (1993). Multiple-Dose Pharmacokinetics of Ramipril in Patients with Chronic Congestive Heart Failure. Journal of Cardiovascular Pharmacology. 22. S36–S36. 10 indexed citations

11.

Heintz, Bernhard, M. Verho, D. Brockmeier, et al.. (1991). Influence of Ramipril on Renal Function in Patients with Chronic Congestive Heart Failure. Journal of Cardiovascular Pharmacology. 18. S174–S179. 2 indexed citations

12.

Verho, M., et al.. (1991). Antihypertensive Efficacy, Tolerance, and Safety of Long-Term Treatment with Ramipril in Patients with Mild-to-Moderate Essential Hypertension. Journal of Cardiovascular Pharmacology. 18. S137–S140. 1 indexed citations

13.

Badian, M., et al.. (1990). Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium. European Journal of Clinical Pharmacology. 38(1). 61–65. 48 indexed citations

14.

Brockmeier, D., Wolfgang Henke, E. Mutschler, et al.. (1988). Penbutolol: Pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding. European Journal of Clinical Pharmacology. 35(6). 613–623. 3 indexed citations

15.

Car, Nikica, Z Škrabalo, & M. Verho. (1988). The effects of piretanide in patients with congestive heart failure and diabetes mellitus: a double-blind comparison with furosemide. Current Medical Research and Opinion. 11(2). 133–141. 4 indexed citations

16.

Badian, M., et al.. (1988). Safety, Tolerance and Pharmacokinetics of 2.0 g Cefpirome (HR 810) after Single and Multiple Dosing. Chemotherapy. 34(5). 367–373. 14 indexed citations

17.

Verho, M., A. Korn, M. Badian, V. Malerczyk, & W. Waldhäusl. (1988). Dose Linearity Testing of Intravenous Ofloxacin, a Novel Gyrase Inhibitor. Chemotherapy. 34(3). 170–177. 4 indexed citations

18.

Verho, M., et al.. (1987). Absence of interaction between ofloxacin and phenprocoumon. Current Medical Research and Opinion. 10(7). 474–479. 9 indexed citations

19.

Verho, M., et al.. (1987). Lack of effect of piretanide (a potassium-stable diuretic) on serum magnesium.. PubMed. 7(6). 433–42. 2 indexed citations

20.

Verho, M., et al.. (1986). Efficacy of a low fixed-dose combination of penbutolol with piretanide in the treatment of mild to moderate hypertension: a double-blind study against placebo.. PubMed. 4(9). 607–16. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact